NICE issued guidance on CV risk assessment and lipid modification in June 2008. The important changes are discussed in the MeReC Stop Press, which should be read in conjunction with the materials in this room of NPCi.
MHRA advice re fibrates - Drug Safety Update Vol 1, Issue 4. 4th. November 2007
The MHRA has issued revised advice to prescribers concerning the place in therapy of fibrates: "Fibrates should be used as first-line therapy only in patients with isolated severe hypertriglyceridaemia. In patients who also have raised cholesterol, fibrates may be considered only when a statin or other effective treatments are contraindicated or not tolerated".
This is discussed in a MeReC Stop Press, which should be read in conjunction with the materials in this room of NPCi.
Note that some of the materials apply the black triangle (▼) to rosuvastatin. This was correct at their time of publication but the black triangle was removed by the MHRA in June 2007
A guide to the support materials for this topic is available in the library.
Test your knowledge (or just have some fun) by answering the questions in this quiz. Suggested answers are given after each question with some additional information and references. You even get a score at the end that you can print out and put in your CPD folder!
Quiz